Sarepta Therapeutics (NASDAQ:SRPT) Given Buy Rating at Needham & Company LLC

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report)'s stock had its "buy" rating reaffirmed by equities research analysts at Needham & Company LLC in a report released on Thursday,Benzinga reports. They currently have a $202.00 target price on the biotechnology company's stock. Needham & Company LLC's price objective would indicate a potential upside of 99.57% from the company's current price.

Other analysts have also recently issued reports about the company. Evercore ISI cut their price target on Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating on the stock in a research note on Thursday, November 7th. Robert W. Baird lowered their target price on Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating on the stock in a research note on Thursday, November 7th. HC Wainwright restated a "sell" rating and issued a $75.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday. Piper Sandler cut their price target on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating for the company in a report on Wednesday, November 27th. Finally, Guggenheim lifted their price target on Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $173.52.

Sarepta Therapeutics Trading Down 5.2 %

Shares of Sarepta Therapeutics stock traded down $5.53 on Thursday, reaching $101.22. The company had a trading volume of 1,354,604 shares, compared to its average volume of 867,510. Sarepta Therapeutics has a 52-week low of $100.14 and a 52-week high of $173.25. The firm's 50 day moving average price is $115.89 and its two-hundred day moving average price is $122.46. The firm has a market cap of $9.67 billion, a PE ratio of 80.98 and a beta of 0.75. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.

Insider Buying and Selling at Sarepta Therapeutics

In other news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company's stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the transaction, the director now directly owns 22,840 shares of the company's stock, valued at $2,851,345.60. This represents a 31.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the transaction, the director now owns 5,880 shares of the company's stock, valued at $738,234. This trade represents a 21.77 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.70% of the company's stock.

Institutional Trading of Sarepta Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. CIBC Asset Management Inc raised its holdings in shares of Sarepta Therapeutics by 3.3% in the 3rd quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company's stock worth $339,000 after purchasing an additional 86 shares during the period. Louisiana State Employees Retirement System lifted its position in shares of Sarepta Therapeutics by 0.4% during the 4th quarter. Louisiana State Employees Retirement System now owns 26,500 shares of the biotechnology company's stock valued at $3,222,000 after buying an additional 100 shares during the last quarter. EP Wealth Advisors LLC grew its stake in shares of Sarepta Therapeutics by 2.2% during the 4th quarter. EP Wealth Advisors LLC now owns 4,988 shares of the biotechnology company's stock worth $606,000 after acquiring an additional 105 shares during the period. Manchester Capital Management LLC increased its holdings in Sarepta Therapeutics by 86.6% in the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 110 shares during the last quarter. Finally, UMB Bank n.a. raised its stake in Sarepta Therapeutics by 36.0% in the 4th quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company's stock valued at $63,000 after acquiring an additional 138 shares during the period. 86.68% of the stock is owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.